News from the FDA/CDC

As FDA OKs another COVID booster, some experts question need


 

Supply issues?

Meanwhile, the United Kingdom has begun offering boosters to anyone over 75, and Sweden’s health authority has recommended a fourth shot to people over age 80.

That puts pressure on the United States — at least on its politicians and policymakers — to, in a sense, keep up, said the infectious disease specialists.

Indeed, the White House has been keeping fourth shots in the news, warning that it is running out of money to ensure that all Americans would have access to one, if recommended.

On March 23, outgoing White House COVID-19 Response Coordinator Jeff Zients said the federal government had enough vaccine for the immunocompromised to get a fourth dose “and, if authorized in the coming weeks, enough supply for fourth doses for our most vulnerable, including seniors.”

But he warned that without congressional approval of a COVID-19 funding package, “We can’t procure the necessary vaccine supply to support fourth shots for all Americans.”

Mr. Zients also noted that other countries, including Japan, Vietnam, and the Philippines had already secured future booster doses and added, “We should be securing additional supply right now.”

Dr. Schaffner says that while it would be nice to “have a booster on the shelf,” the United States needs to put more effort into creating a globally-coordinated process for ensuring that vaccines match circulating strains and that they are manufactured on a timely basis.

He says he and others “have been reminding the public that the COVID pandemic may indeed be diminishing and moving into the endemic, but that doesn’t mean COVID is over or finished or disappeared.”

Dr. Schaffner says that it may be that “perhaps we’d need a periodic reminder to our immune system to remain protected. In other words, we might have to get boosted perhaps annually like we do with influenza.”

A version of this article first appeared on WebMD.com.

Pages

Recommended Reading

COVID-19 vax effectiveness quantified in immunosuppressed patients
MDedge Dermatology
Biden administration’s new test-to-treat program pits pharmacists against physicians
MDedge Dermatology
New ACC guidance on cardiovascular consequences of COVID-19
MDedge Dermatology
COVID surge in Western Europe puts U.S. health experts on alert
MDedge Dermatology
COVID-19–alopecia areata link? Review doesn’t find much evidence
MDedge Dermatology
U.S. health officials tracking COVID-19 increase in U.K.
MDedge Dermatology
‘Profound implications’: COVID ups diabetes risk 40% a year later
MDedge Dermatology
Natural, vaccine-induced, and hybrid immunity to COVID-19
MDedge Dermatology
COVID-19 infection linked to risk of cutaneous autoimmune and vascular diseases
MDedge Dermatology
Aluminum named allergen of the year
MDedge Dermatology